Tandem mass spectrometry

Newborn Screening Market Analysis Report 2023 - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 16, 2024
Other Health, Consumer, Health, Genetics, Baby, Maternity, Abnormality, DSM-IV codes, Tandem mass spectrometry, Gene, Hospital, Prevalence, Growth, Pharmaceutical industry

The "Newborn Screening Market by Product Technology Application End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Newborn Screening Market by Product Technology Application End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global newborn screening market is projected to reach $2.49 billion by 2030, at a CAGR of 7.9% from 2023 to 2030.
  • Among products, in 2023, the consumables segment is expected to account for the largest share of the newborn screening market.
  • Among applications, in 2023, the inherited disorders segment is expected to account for the largest share of the newborn screening market.

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development

Retrieved on: 
Thursday, December 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Chem, Tandem mass spectrometry, QPS, Chemistry, GLP, University of California, Berkeley, Peptide, Physikalisch-Technische Bundesanstalt, Diples, Multimedia, Daniel, LC-MS, Master of Science, Therapy, University of Kassel, Mass spectrometry, Drug discovery, University, Doctor of Philosophy, Biomarker, Oligonucleotide, UC, Drug development, LC-MS/MS, Fine chemical, Medtronic, Bioanalysis

QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.

Key Points: 
  • QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
  • This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.
  • With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development.

'Eco-friendly' straws contain potentially toxic chemicals – posing a threat to people and wildlife

Retrieved on: 
Wednesday, August 30, 2023
People, Heart, Human, Food, TFA, PFAS, Metal, Serum, Method, Infection, Skin, Research, Cape Fear, COVID, Plant, Neoplasm, Climate change, Animal, Soil, Chromium, Nickel, Risk, Water, Fertility, Cancer, European, Dust, Paper, Liver, Pregnancy, Trifluoroacetic acid, Environment, Bird, Tandem mass spectrometry, Hydrocarbon, Cosmetics, Environmental remediation

Drinking straws that are made from materials like paper and bamboo are often promoted as more eco-friendly than their plastic counterparts.

Key Points: 
  • Drinking straws that are made from materials like paper and bamboo are often promoted as more eco-friendly than their plastic counterparts.
  • However, a new study has found that these supposedly sustainable straws contain potentially toxic chemicals called polyfluoroalkyl and perfluoroalkyl substances (PFAS).
  • The study, conducted by researchers in Belgium, analysed commercially available drinking straws of various types and recorded PFAS concentrations in 39 separate brands.

Detecting forever chemicals

    • A screening approach was then used to detect any other PFAS compounds in the straws.
    • This revealed the presence of two additional PFAS compounds – trifluoroacetic acid (TFA) and trifluoromethanesulfonic acid (TFMS).
    • However, they are known to be associated with sites where firefighting foams have been used.

Should we be concerned?

    • PFAS exposure poses considerable health risks to people, wildlife and the environment.
    • Research indicates that pregnant women who are exposed to these substances may experience reduced fertility and heightened blood pressure.
    • Their children could face developmental effects like low birth weight, early puberty and even an increased risk of some cancers.
    • Every Wednesday, The Conversation’s environment editor writes Imagine, a short email that goes a little deeper into just one climate issue.

Intelligent Bio Solutions Plans to Add Fentanyl Testing as it Further Enhances its Fingerprint-Based Drug Screening Solution

Retrieved on: 
Tuesday, May 16, 2023
LC-MS/MS, Methamphetamine, Urine, Mass spectrometry, Fentanyl, Chromatography, Heroin, CDC, Death, Cocaine, Tandem mass spectrometry, Cannabis, Tranquilizer, Intelligence, Drug

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced plans to add the potent synthetic opioid drug, fentanyl, and fentanyl-adulterated street drugs, to the panel of substances detected by its lab-based confirmation testing using fingertip sweat collected by its proprietary Intelligent Fingerprinting Drug Screening System.

Key Points: 
  • The Company is combatting this healthcare crisis by expanding the capabilities of its lab-based confirmation testing service to detect fentanyl and its related analogues in samples collected by its fingerprint-based drug testing system.
  • “By seeking to add fentanyl and other fentanyl-adulterated street drugs to our fingerprint-based lab-based confirmation drug testing panel, we are furthering our commitment to equipping workplaces to better combat the opioid issue.
  • We believe making drug testing for fentanyl non-invasive, quick, and hygienic is an important step towards addressing this crisis,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions.
  • Fingerprint testing provides a quick and dignified approach that is much more convenient than traditional urine or saliva drug testing methods.

Quest Diagnostics Extends Alzheimer's Disease Portfolio with New AI-Powered Test Service from uMETHOD Health

Retrieved on: 
Thursday, May 4, 2023
Quest Diagnostics, Centers for Medicare & Medicaid Services, DSM-IV codes, Dementia, Risk assessment, Risk, History, DGX, Science, Medicare, NYSE, Tandem mass spectrometry, MD, Patient, Physician, Medicine, Conditional sentence, Artificial intelligence, Health, FAAN, Disease, Medical device, Pharmaceutical industry, Medical imaging, Quest, Alzheimer's disease, Neurology

SECAUCUS, N.J. and RALEIGH, N.C., May 4, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline.

Key Points: 
  • The service incorporates results of laboratory tests ordered by physicians from Quest Diagnostics along with the patient's health history, including comorbidities, lifestyle habits and medications.
  • RestoreU is available through a collaborative agreement between Quest Diagnostics and uMETHOD, marking the first time the service is available nationwide to physicians.
  • Provider clients of Quest Diagnostics may order the service (as "Dementia Panel – RestoreU") through their electronic health record system.
  • *RestoreU may help physicians satisfy service elements of cognitive care planning as defined under the Centers for Medicare and Medicaid Services.

Denton Vacuum Announces Third Order for Infinity FA Ion Beam Etch Delayering System

Retrieved on: 
Friday, February 10, 2023
Denton, SIMS, Tandem mass spectrometry, FA, Infinity, Mobile phone

MOORESTOWN, N.J., Feb. 10, 2023 /PRNewswire/ -- Denton Vacuum LLC announced today that they have won a third order for the Infinity FA failure analysis system from a leading global semiconductor memory device manufacturer.

Key Points: 
  • MOORESTOWN, N.J., Feb. 10, 2023 /PRNewswire/ -- Denton Vacuum LLC announced today that they have won a third order for the Infinity FA failure analysis system from a leading global semiconductor memory device manufacturer.
  • The Infinity FA is an ion beam etch chip delayering system for semiconductor failure analysis and quality assurance.
  • High ion energies like those in focused ion beam and other ion beam technologies will damage the features of interest, preventing proper failure analysis."
  • Dr. David Douglass, Senior Product Manager at Denton Vacuum, added, "Denton's low ion energy, broad beam etch capability uniquely enables large area, rapid processing of semiconductor devices.

New Release of Genedata Expressionist For Innovative Characterization and Automated Quality Monitoring of Next-Generation Biotherapeutics

Retrieved on: 
Tuesday, October 18, 2022
Time, Molecule, Review, Workflow, Oligonucleotide, CQA, Intelligence, D, Technology, ROI, Automation, Knowledge, Solution, Drug discovery, Industry, Mass spectrometry, CEO, Safety, Tandem mass spectrometry, Data analysis, MS/MS, Fine chemical, Genedata

BASEL, Switzerland, Oct. 18, 2022 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Expressionist® 16.5, the latest version of its platform for streamlining and automating mass spectrometry data workflows, from early discovery to late-stage development. Genedata Expressionist 16.5 takes characterization and quality monitoring of biotherapeutics and oligonucleotides to the next level by enabling leading biopharma companies to fully leverage the potential of mass spectrometry data in their R&D workflows, irrespective of the instrument or technology applied.

Key Points: 
  • Genedata Expressionist 16.5 takes characterization and quality monitoring of biotherapeutics and oligonucleotides to the next level by enabling leading biopharma companies to fully leverage the potential of mass spectrometry data in their R&D workflows, irrespective of the instrument or technology applied.
  • This release further enhances the established characterization workflows built into Genedata Expressionist for the identification of multiple clipping events in biotherapeutics.
  • As the industry leader in end-to-end automation of MS data analysis, Genedata Expressionist now offers automated product quality monitoring of emerging modalitiessuch as therapeutic oligonucleotides.
  • "The inherent complexity of innovative biotherapeutics necessitates comprehensive characterization and robust product quality assessment.

Denton Vacuum Announces Follow-On Order for Infinity FA Ion Beam Etch Delayering System

Retrieved on: 
Thursday, July 14, 2022
Technology, Failure analysis, SIMS, State Farm Research and Development Center, Denton, Multimedia, Development, IR, Infinity, CEO, Tandem mass spectrometry, Research, FA, Efficiency, Computer data storage

MOORESTOWN, N.J., July 14, 2022 /PRNewswire/ -- Denton Vacuum LLC today announced it won a repeat system order for its Infinity FA failure analysis system from a leading global semiconductor memory device manufacturer.

Key Points: 
  • MOORESTOWN, N.J., July 14, 2022 /PRNewswire/ -- Denton Vacuum LLC today announced it won a repeat system order for its Infinity FA failure analysis system from a leading global semiconductor memory device manufacturer.
  • The Infinity FA is an ion beam etch chip delayering system for semiconductor failure analysis and quality assurance.
  • Dr. David Douglass, Senior Product Manager at Denton Vacuum, commented, "Denton's low ion energy, broad beam etch capability uniquely enables large area, rapid processing of semiconductor devices.
  • The Infinity FA can rapidly etch highly uniform, planar, large areas of interest.

Quest Diagnostics Presents Late Breaker Study Demonstrating Diabetes Prescription Cost Reductions Achieved for Participants in an Employer-Sponsored Health Program at the 82nd American Diabetes Association Scientific Sessions

Retrieved on: 
Monday, June 6, 2022
People, Digital health, Conditional sentence, Association, Liver disease, Adult, Program, Directory, Research, T2DM, Type 2 diabetes, ADA, Food, Obesity, Database, Disease, BMI, Multimedia, Insulin resistance, Physician, Endocrine system, Diagnosis, Population Health Management, Patient, Tandem mass spectrometry, Hospital, Diabetes, Body mass index, Risk, HDL, PON3, T2D, NYSE, Health, DGX, Poster, MD, Population, Cleveland, A1C, APOM, Prescription, LDL, Waist, Pharmaceutical industry, Medical device, Health insurance, Quest Diagnostics, Quest

SECAUCUS, N.J. , June 6, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it presented results of six studies at the 82nd American Diabetes Association Scientific Sessions, June 3-7, 2022 in New Orleans, LA. These studies by researchers from Quest Diagnostics (Booth #1005) include one late breaker and two oral presentations. They provide novel insights into the use of advanced diagnostic technologies, population health management strategies and digital health coaching to improve the diagnosis, treatment, and management of individuals with diabetes.

Key Points: 
  • These studies by researchers from Quest Diagnostics (Booth #1005) include one late breaker and two oral presentations.
  • Participants also experienced improvements in health risk scores, including fasting glucose, weight, body mass index (BMI) and waist circumference.
  • This study was selected as an American Diabetes Association Health Disparities Committee Top 10 Recommended Abstract for its focus on health care disparities and inequities in diabetes outcomes.
  • Full List of Quest Diagnostics Studies:
    A complete list of the Quest Diagnostics research presented at this year's Scientific Sessions:
    Quest Diagnostics empowers people to take action to improve health outcomes.

Is Hybrid LC-MS/MS Becoming the New Gold Standard? Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, April 18, 2022
LC-MS/MS, Food, Technology, Antibody, Industry, Tandem mass spectrometry, Thought, Therapy, Biomarker, Perfume

TORONTO , April 18, 2022  /PRNewswire-PRWeb/ -- Due to the relative maturity of the technology, most people's instincts when thinking about bioanalysis of large molecules is towards ligand binding assays. In this webinar, the featured speakers urge people to be open to a more flexible approach — Hybrid LC-MS/MS.

Key Points: 
  • The featured speakers will discuss case studies illustrating the value of Hybrid LC-MS/MS.
  • In this webinar, the featured speakers urge people to be open to a more flexible approach Hybrid LC-MS/MS.
  • Hybrid liquid chromatography with tandem mass spectrometry (LC-MS/MS) can be a useful tool for quantitation of biological therapeutics and biomarkers.
  • For more information, or to register for this event, visit Is Hybrid LC-MS/MS Becoming the New Gold Standard?.